These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 31339286)
1. [Prostaglandin 12 analogs (epoprostenol and treprostinil) as a treatment for refractory bronchopulmonary dysplasia-induced pulmonary hypertension in an infant]. Puente Ubierna N; Bachiller Carnicero L; Corredera Sánchez A; Martínez Orgado JA; Del Cerro Marín MJ Arch Argent Pediatr; 2019 Aug; 117(4):e413-e415. PubMed ID: 31339286 [TBL] [Abstract][Full Text] [Related]
2. Epoprostenol and home mechanical ventilation for pulmonary hypertension associated with chronic lung disease. Zaidi AN; Dettorre MD; Ceneviva GD; Thomas NJ Pediatr Pulmonol; 2005 Sep; 40(3):265-9. PubMed ID: 15830393 [TBL] [Abstract][Full Text] [Related]
3. Weaning of epoprostenol in a small infant receiving concomitant bosentan for severe pulmonary arterial hypertension secondary to bronchopulmonary dysplasia. Rugolotto S; Errico G; Beghini R; Ilic S; Richelli C; Padovani EM Minerva Pediatr; 2006 Oct; 58(5):491-4. PubMed ID: 17008861 [TBL] [Abstract][Full Text] [Related]
4. Short term effect of intravenous treprostinil in term and preterm infants with pulmonary hypertension. Kim YJ; Shin SH; Kim EK; Kim HS BMC Pediatr; 2024 Jan; 24(1):83. PubMed ID: 38281939 [TBL] [Abstract][Full Text] [Related]
5. Severe pulmonary arterial hypertension in a very premature baby with bronchopulmonary dysplasia: normalization with long-term sildenafil. Caputo S; Furcolo G; Rabuano R; Basilicata AM; Pilla LM; De Simone A; Pasquariello B; Ciampi Q; Vetrano G; Villari B J Cardiovasc Med (Hagerstown); 2010 Sep; 11(9):704-6. PubMed ID: 19829144 [TBL] [Abstract][Full Text] [Related]
6. Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension. Voswinckel R; Reichenberger F; Enke B; Kreckel A; Krick S; Gall H; Schermuly RT; Grimminger F; Rubin LJ; Olschewski H; Seeger W; Ghofrani HA Pulm Pharmacol Ther; 2008 Oct; 21(5):824-32. PubMed ID: 18657627 [TBL] [Abstract][Full Text] [Related]
7. The potential for inhaled treprostinil in the treatment of pulmonary arterial hypertension. Gessler T; Seeger W; Schmehl T Ther Adv Respir Dis; 2011 Jun; 5(3):195-206. PubMed ID: 21300738 [TBL] [Abstract][Full Text] [Related]
8. Safety and tolerability of subcutaneous treprostinil in newborns with congenital diaphragmatic hernia and life-threatening pulmonary hypertension. Carpentier E; Mur S; Aubry E; Pognon L; Rakza T; Flamein F; Sharma D; Tourneux P; Storme L J Pediatr Surg; 2017 Sep; 52(9):1480-1483. PubMed ID: 28389079 [TBL] [Abstract][Full Text] [Related]
9. Oral sildenafil for treatment of severe pulmonary hypertension in an infant. Hon KL; Cheung KL; Siu KL; Leung TF; Yam MC; Fok TF; Ng PC Biol Neonate; 2005; 88(2):109-12. PubMed ID: 15870496 [TBL] [Abstract][Full Text] [Related]
10. Short-Term Treprostinil Use in Infants with Congenital Diaphragmatic Hernia following Repair. Olson E; Lusk LA; Fineman JR; Robertson L; Keller RL J Pediatr; 2015 Sep; 167(3):762-4. PubMed ID: 26143384 [TBL] [Abstract][Full Text] [Related]
11. Pulmonary hypertension in bronchopulmonary dysplasia. Ambalavanan N; Mourani P Birth Defects Res A Clin Mol Teratol; 2014 Mar; 100(3):240-6. PubMed ID: 24616323 [TBL] [Abstract][Full Text] [Related]
12. Overview of treprostinil sodium for the treatment of pulmonary arterial hypertension. Budev MM; Minai OA; Arroliga AC Drugs Today (Barc); 2004 Mar; 40(3):225-34. PubMed ID: 15148531 [TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension. Keogh AM; Jabbour A; Weintraub R; Brown K; Hayward CS; Macdonald PS J Heart Lung Transplant; 2007 Nov; 26(11):1079-83. PubMed ID: 18022071 [TBL] [Abstract][Full Text] [Related]
14. Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension. Sitbon O; Manes A; Jais X; Pallazini M; Humbert M; Presotto L; Paillette Ld; Zaccardelli D; Davis G; Jeffs R; Simonneau G; Galie N J Cardiovasc Pharmacol; 2007 Jan; 49(1):1-5. PubMed ID: 17261956 [TBL] [Abstract][Full Text] [Related]
15. Treprostinil for pulmonary hypertension. Skoro-Sajer N; Lang I; Naeije R Vasc Health Risk Manag; 2008; 4(3):507-13. PubMed ID: 18827901 [TBL] [Abstract][Full Text] [Related]
16. Inhaled treprostinil for the treatment of pulmonary arterial hypertension. LeVarge BL; Channick RN Expert Rev Respir Med; 2012 Jun; 6(3):255-65. PubMed ID: 22788940 [TBL] [Abstract][Full Text] [Related]
17. Treprostinil for the treatment of pulmonary arterial hypertension. Torres F; Rubin LJ Expert Rev Cardiovasc Ther; 2013 Jan; 11(1):13-25. PubMed ID: 23259441 [TBL] [Abstract][Full Text] [Related]
18. An Echocardiographic Screening Program Helps to Identify Pulmonary Hypertension in Extremely Low Birthweight Infants with and without Bronchopulmonary Dysplasia: A Single-Center Experience. Mehler K; Udink Ten Cate FE; Keller T; Bangen U; Kribs A; Oberthuer A Neonatology; 2018; 113(1):81-88. PubMed ID: 29131022 [TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of treprostinil versus epoprostenol in patients with pulmonary arterial hypertension: a Canadian analysis. Einarson TR; Granton JT; Vicente C; Walker J; Engel G; Iskedjian M Can Respir J; 2005; 12(8):419-25. PubMed ID: 16331313 [TBL] [Abstract][Full Text] [Related]